Lite Strategy, Inc. LITS
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-59.27
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$15.9M | — | -$20.8M | $16.9M |
| 2024 | $65.3M | $17.8M | — | -$50.5M | $33.0M |
| 2023 | $48.8M | -$32.0M | — | -$52.5M | $24.6M |
| 2022 | $40.7M | -$54.5M | — | -$49.2M | $52.4M |
| 2021 | $34.8M | -$41.3M | — | -$32.7M | $49.5M |
| 2020 | $27.8M | -$47.2M | — | $33.4M | $77.1M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Flynn James P | director | 2026-06-24 | Buy | 25,000 | $0.86 |
| Flynn James P | director | 2025-12-19 | Buy | 70,000 | $1.40 |
| Schornstein Alexander | 10% owner | 2025-12-18 | Sell | 690,611 | $1.37 |
| Flynn James P | director | 2025-11-19 | Buy | 12,100 | $1.88 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -59.27 (distress)
- Working capital / assets 0.926
- Retained earnings / assets -22.104
- EBIT / assets -0.955
- Equity / liabilities 12.504
Source: SEC EDGAR filings · CIK 0001262104 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.